Kurs
-2,64%
Likviditet
2,31 MSEK
Prenumeration
Kalender
Tid* | ||
2026-02-05 | 07:30 | Bokslutskommuniké 2025 |
2025-11-06 | 07:30 | Kvartalsrapport 2025-Q3 |
2025-07-18 | 07:30 | Kvartalsrapport 2025-Q2 |
2025-05-06 | N/A | Årsstämma |
2025-04-29 | 07:30 | Kvartalsrapport 2025-Q1 |
2025-02-06 | 07:30 | Bokslutskommuniké 2024 |
2024-10-24 | - | Kvartalsrapport 2024-Q3 |
2024-07-19 | - | Kvartalsrapport 2024-Q2 |
2024-05-06 | - | X-dag ordinarie utdelning CEVI 2.25 SEK |
2024-05-03 | - | Årsstämma |
2024-05-03 | - | X-dag ordinarie utdelning CEVI 2.25 SEK |
2024-04-25 | - | Kvartalsrapport 2024-Q1 |
2024-02-07 | - | Bokslutskommuniké 2023 |
2023-10-25 | - | Kvartalsrapport 2023-Q3 |
2023-07-20 | - | Kvartalsrapport 2023-Q2 |
2023-05-08 | - | X-dag ordinarie utdelning CEVI 2.25 SEK |
2023-05-05 | - | Årsstämma |
2023-05-05 | - | X-dag ordinarie utdelning CEVI 2.25 SEK |
2023-05-04 | - | Kvartalsrapport 2023-Q1 |
2023-02-07 | - | Bokslutskommuniké 2022 |
2022-10-26 | - | Kvartalsrapport 2022-Q3 |
2022-07-20 | - | Kvartalsrapport 2022-Q2 |
2022-05-12 | - | X-dag ordinarie utdelning CEVI 2.00 SEK |
2022-05-11 | - | Årsstämma |
2022-05-10 | - | Kvartalsrapport 2022-Q1 |
2022-02-04 | - | Bokslutskommuniké 2021 |
2021-10-22 | - | Kvartalsrapport 2021-Q3 |
2021-07-20 | - | Kvartalsrapport 2021-Q2 |
2021-04-30 | - | X-dag ordinarie utdelning CEVI 0.75 SEK |
2021-04-29 | - | Årsstämma |
2021-04-28 | - | Kvartalsrapport 2021-Q1 |
2021-02-04 | - | Bokslutskommuniké 2020 |
2020-10-23 | - | Kvartalsrapport 2020-Q3 |
2020-07-16 | - | Kvartalsrapport 2020-Q2 |
2020-06-17 | - | X-dag ordinarie utdelning CEVI 0.00 SEK |
2020-06-16 | - | Årsstämma |
2020-04-22 | - | Kvartalsrapport 2020-Q1 |
2020-02-05 | - | Bokslutskommuniké 2019 |
2019-10-23 | - | Kvartalsrapport 2019-Q3 |
2019-07-16 | - | Kvartalsrapport 2019-Q2 |
2019-05-09 | - | X-dag ordinarie utdelning CEVI 1.50 SEK |
2019-05-08 | - | Årsstämma |
2019-05-07 | - | Kvartalsrapport 2019-Q1 |
2019-02-07 | - | Bokslutskommuniké 2018 |
2018-10-23 | - | Kvartalsrapport 2018-Q3 |
2018-07-19 | - | Kvartalsrapport 2018-Q2 |
2018-05-07 | - | X-dag ordinarie utdelning CEVI 1.50 SEK |
2018-05-04 | - | Årsstämma |
2018-05-03 | - | Kvartalsrapport 2018-Q1 |
2018-02-09 | - | Bokslutskommuniké 2017 |
2017-10-25 | - | Kvartalsrapport 2017-Q3 |
2017-07-18 | - | Kvartalsrapport 2017-Q2 |
2017-05-08 | - | X-dag ordinarie utdelning CEVI 1.50 SEK |
2017-05-05 | - | Årsstämma |
2017-05-04 | - | Kvartalsrapport 2017-Q1 |
2017-02-07 | - | Bokslutskommuniké 2016 |
2016-10-27 | - | Kvartalsrapport 2016-Q3 |
2016-07-15 | - | Kvartalsrapport 2016-Q2 |
2016-05-06 | - | X-dag ordinarie utdelning CEVI 1.50 SEK |
2016-05-04 | - | Årsstämma |
2016-05-03 | - | Kvartalsrapport 2016-Q1 |
2016-02-12 | - | Bokslutskommuniké 2015 |
2015-11-09 | - | Kvartalsrapport 2015-Q3 |
2015-07-17 | - | Kvartalsrapport 2015-Q2 |
2015-05-07 | - | X-dag ordinarie utdelning CEVI 1.00 SEK |
2015-05-06 | - | Årsstämma |
2015-05-05 | - | Kvartalsrapport 2015-Q1 |
2015-02-12 | - | Bokslutskommuniké 2014 |
2014-11-05 | - | Kvartalsrapport 2014-Q3 |
2014-07-18 | - | Kvartalsrapport 2014-Q2 |
2014-05-08 | - | X-dag ordinarie utdelning CEVI 0.50 SEK |
2014-05-07 | - | Årsstämma |
2014-05-06 | - | Kvartalsrapport 2014-Q1 |
2014-02-13 | - | Bokslutskommuniké 2013 |
2013-10-24 | - | Kvartalsrapport 2013-Q3 |
2013-07-17 | - | Kvartalsrapport 2013-Q2 |
2013-04-25 | - | X-dag ordinarie utdelning CEVI 0.40 SEK |
2013-04-24 | - | Årsstämma |
2013-04-24 | - | Kvartalsrapport 2013-Q1 |
2013-02-14 | - | Bokslutskommuniké 2012 |
2012-10-26 | - | Kvartalsrapport 2012-Q3 |
2012-07-18 | - | Kvartalsrapport 2012-Q2 |
2012-05-24 | - | Kapitalmarknadsdag 2012 |
2012-05-03 | - | X-dag ordinarie utdelning CEVI 0.40 SEK |
2012-05-02 | - | Årsstämma |
2012-04-25 | - | Kvartalsrapport 2012-Q1 |
2012-02-14 | - | Bokslutskommuniké 2011 |
2011-10-25 | - | Kvartalsrapport 2011-Q3 |
2011-07-15 | - | Kvartalsrapport 2011-Q2 |
2011-04-27 | - | X-dag ordinarie utdelning CEVI 0.00 SEK |
2011-04-26 | - | Årsstämma |
2011-04-20 | - | Kvartalsrapport 2011-Q1 |
2011-02-15 | - | Bokslutskommuniké 2010 |
2010-10-27 | - | Kvartalsrapport 2010-Q3 |
2010-07-16 | - | Kvartalsrapport 2010-Q2 |
2010-04-30 | - | X-dag ordinarie utdelning CEVI 0.00 SEK |
2010-04-29 | - | Kvartalsrapport 2010-Q1 |
2010-02-12 | - | Bokslutskommuniké 2009 |
2009-10-23 | - | Kvartalsrapport 2009-Q3 |
2009-07-15 | - | Kvartalsrapport 2009-Q2 |
2009-04-27 | - | Årsstämma |
2009-04-27 | - | Kvartalsrapport 2009-Q1 |
Beskrivning
Land | Sverige |
---|---|
Lista | Mid Cap Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
Ahead of the Annual General Meeting 2025, the Nomination Committee consists of:
- Christer Fåhraeus, Christer Fåhraeus with Companies
- Nicklas Hansen, William Demant Invest A/S
- Anette Andersson, SEB Investment funds
- Emil Hjalmarsson, Grenlunden CEVI AB
Emil Hjalmarsson has been appointed Chairman of the Nomination Committee.
The Nomination Committee shall prepare proposals for the Annual General Meeting in 2025 regarding the election of Chairman of the General Meeting, members of the Board of Directors, Chairman of the Board, auditor, fees for the members of the Board including division between the Chairman, and the other Board members as well as fees for committee work and fees to the company’s auditor.
The CellaVision Annual General Meeting in 2025 will be held in Lund at 15:00 o´clock CEST, on May 6, 2025.
Shareholders wishing to have matters considered at the Annual General Meeting can send a written request by email to: bolagsstamma@cellavision.se, or ordinary mail addressed to: The Board of Directors, CellaVision AB, Mobilvägen 12, 223 62 Lund. The request must have been received at the latest seven weeks before the Annual General Meeting in order to be included in the notice to attend and thus the agenda of the Annual General Meeting.
Contact
Adele Horn
Corporate Communications & Investor Relations Manager
Tel: + 46 46 460 26 04
www.cellavision.com
adele.horn@cellavision.com
About Us
CellaVision is a global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. These analyses play a vital role in swift and accurate disease diagnoses, particularly in cases of infections and serious cancer diseases. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company´s 12 local market support organizations covering more than 40 countries. In 2023, sales were SEK 677 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com